Last reviewed · How we verify
ARRY-300, MEK inhibitor; oral
MEK inhibitor
MEK inhibitor Used for Non-small cell lung cancer.
At a glance
| Generic name | ARRY-300, MEK inhibitor; oral |
|---|---|
| Sponsor | Array Biopharma, now a wholly owned subsidiary of Pfizer |
| Drug class | MEK inhibitor |
| Target | MEK1/2 |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 1 |
Mechanism of action
ARRY-300 is a small molecule inhibitor of the MEK1/2 enzyme, which is involved in the MAPK/ERK signaling pathway.
Approved indications
- Non-small cell lung cancer
Common side effects
- Diarrhea
- Nausea
- Vomiting
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: